Arcturus Therapeutics Holdings Inc. Common Stock
ARCTArcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing next-generation RNA medicines and vaccines. Established with the aim of transforming the treatment of rare and infectious diseases, Arcturus leverages its proprietary LUNAR lipid-mediated delivery platform to enhance the efficacy of RNA-based therapeutics. The company primarily engages in research, development, and commercialization efforts within the fields of immunology, neurology, and genetic disorders.
Company News
Cathie Wood of Ark Invest purchased shares of Robinhood Markets, Netflix, and Arcturus Therapeutics on Wednesday, taking advantage of recent stock price dips and seeing potential growth opportunities in these companies.
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
The Lipid Nanoparticles (LNPs) market is projected to grow from $1 billion in 2024 to $3.5 billion by 2034, driven by increasing demand for mRNA-based therapeutics and advances in drug delivery systems.
The global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a CAGR of 68%, driven by advancements in RNA technologies and next-generation therapies.
The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.
